Profile of tocilizumab and its potential in the treatment of giant cell arteritis
Susan Patricia Mollan,1,2 John Horsburgh,1 Bhaskar Dasgupta3 1Birmingham Neuro-Ophthalmology Unit, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham, 2Institute of Metabolism and Systems Research, University of Birmingham, 3Department of Rheumatology, Southen...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2018-01-01
|
| Series: | Eye and Brain |
| Subjects: | |
| Online Access: | https://www.dovepress.com/profile-of-tocilizumab-and-its-potential-in-the-treatment-of-giant-cel-peer-reviewed-article-EB |
| _version_ | 1828815941853511680 |
|---|---|
| author | Mollan SP Horsburgh J Dasgupta B |
| author_facet | Mollan SP Horsburgh J Dasgupta B |
| author_sort | Mollan SP |
| collection | DOAJ |
| description | Susan Patricia Mollan,1,2 John Horsburgh,1 Bhaskar Dasgupta3 1Birmingham Neuro-Ophthalmology Unit, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham, 2Institute of Metabolism and Systems Research, University of Birmingham, 3Department of Rheumatology, Southend University Hospital, Southend-on-Sea, UK Abstract: Giant cell arteritis (GCA) remains a medical emergency due to the threat of permanent sight loss. High-dose glucocorticoids (GCs) are effective in inducing remission in the majority of patients, however, relapses are common which lengthen GC therapy. GC toxicity remains a major morbidity in this group of patients, and conventional steroid-sparing therapies have not yet shown enough of a clinical benefit to change the standard of care. As the understanding of the underlying immunopathophysiology of GCA has increased, positive clinical observations have been made with the use of IL-6 receptor inhibitor therapies, such as tocilizumab (TCZ). This has led to prospective randomized control trials that have highlighted the safety and efficacy of TCZ in both new-onset and relapsing GCA. Keywords: giant cell arteritis, temporal arteritis, Horton disease, interleukin-6, tocilizumab, treatment |
| first_indexed | 2024-12-12T10:54:03Z |
| format | Article |
| id | doaj.art-3fe1447fd5094055ba849b076e5a6310 |
| institution | Directory Open Access Journal |
| issn | 1179-2744 |
| language | English |
| last_indexed | 2024-12-12T10:54:03Z |
| publishDate | 2018-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Eye and Brain |
| spelling | doaj.art-3fe1447fd5094055ba849b076e5a63102022-12-22T00:26:43ZengDove Medical PressEye and Brain1179-27442018-01-01Volume 1011136504Profile of tocilizumab and its potential in the treatment of giant cell arteritisMollan SPHorsburgh JDasgupta BSusan Patricia Mollan,1,2 John Horsburgh,1 Bhaskar Dasgupta3 1Birmingham Neuro-Ophthalmology Unit, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham, 2Institute of Metabolism and Systems Research, University of Birmingham, 3Department of Rheumatology, Southend University Hospital, Southend-on-Sea, UK Abstract: Giant cell arteritis (GCA) remains a medical emergency due to the threat of permanent sight loss. High-dose glucocorticoids (GCs) are effective in inducing remission in the majority of patients, however, relapses are common which lengthen GC therapy. GC toxicity remains a major morbidity in this group of patients, and conventional steroid-sparing therapies have not yet shown enough of a clinical benefit to change the standard of care. As the understanding of the underlying immunopathophysiology of GCA has increased, positive clinical observations have been made with the use of IL-6 receptor inhibitor therapies, such as tocilizumab (TCZ). This has led to prospective randomized control trials that have highlighted the safety and efficacy of TCZ in both new-onset and relapsing GCA. Keywords: giant cell arteritis, temporal arteritis, Horton disease, interleukin-6, tocilizumab, treatmenthttps://www.dovepress.com/profile-of-tocilizumab-and-its-potential-in-the-treatment-of-giant-cel-peer-reviewed-article-EBGiant Cell ArteritisTemporal ArteritisHorton DiseaseInterleukin-6TocilizumabTreatment |
| spellingShingle | Mollan SP Horsburgh J Dasgupta B Profile of tocilizumab and its potential in the treatment of giant cell arteritis Eye and Brain Giant Cell Arteritis Temporal Arteritis Horton Disease Interleukin-6 Tocilizumab Treatment |
| title | Profile of tocilizumab and its potential in the treatment of giant cell arteritis |
| title_full | Profile of tocilizumab and its potential in the treatment of giant cell arteritis |
| title_fullStr | Profile of tocilizumab and its potential in the treatment of giant cell arteritis |
| title_full_unstemmed | Profile of tocilizumab and its potential in the treatment of giant cell arteritis |
| title_short | Profile of tocilizumab and its potential in the treatment of giant cell arteritis |
| title_sort | profile of tocilizumab and its potential in the treatment of giant cell arteritis |
| topic | Giant Cell Arteritis Temporal Arteritis Horton Disease Interleukin-6 Tocilizumab Treatment |
| url | https://www.dovepress.com/profile-of-tocilizumab-and-its-potential-in-the-treatment-of-giant-cel-peer-reviewed-article-EB |
| work_keys_str_mv | AT mollansp profileoftocilizumabanditspotentialinthetreatmentofgiantcellarteritis AT horsburghj profileoftocilizumabanditspotentialinthetreatmentofgiantcellarteritis AT dasguptab profileoftocilizumabanditspotentialinthetreatmentofgiantcellarteritis |